Research
Anhedonia and depression severity measures during ketamine administration in treatment-resistant depression.
Frontiers in psychiatry – January 01, 2024
Summary
Ketamine shows promise in treating one of depression's most challenging symptoms - the inability to feel pleasure. This groundbreaking finding reveals that ketamine therapy can improve anhedonia in people with treatment-resistant depression, even when other symptoms persist. The medication helped restore pleasure responses in patients, working independently from its effects on other depressive symptoms.
Abstract
Anhedonia is a core symptom of depression characterized by a diminished ability to experience pleasure. Currently available treatments for depressi...
Ketamine for depressive symptoms: A retrospective chart review of a private ketamine clinic.
The South African journal of psychiatry : SAJP : the journal of the Society of Psychiatrists of South Africa – January 01, 2024
Summary
Intravenous ketamine offers new hope for people with major depression, showing remarkable success in a South African clinic. Among 154 patients receiving ketamine infusions alongside their usual treatments, over 60% experienced significant improvement after completing the initial induction series. Half of the patients reported complete relief from suicidal thoughts, while one-third achieved full remission. Many continued with maintenance doses, showing no signs of dependency. Side effects were minimal, mainly limited to manageable nausea.
Abstract
There is currently no published evidence demonstrating the effectiveness and safety of subanaesthetic doses of ketamine, when administered intraven...
Conflict monitoring and emotional processing in 3,4-methylenedioxymethamphetamine (MDMA) and methamphetamine users - A comparative neurophysiological study.
NeuroImage. Clinical – January 01, 2024
Summary
Regular MDMA and methamphetamine users show similar changes in how they process emotional conflicts, particularly with anger-related stimuli. Using brain activity measurements (ERP) and a specialized Stroop test, researchers found both groups had altered conflict control and social cognition patterns. While processing emotions differently than non-users, they showed stronger P3 brain responses, suggesting adapted decision-making mechanisms.
Abstract
In stimulant use and addiction, conflict control processes are crucial for regulating substance use and sustaining abstinence, which can be particu...
Quantum-like Qualia hypothesis: from quantum cognition to quantum perception.
Frontiers in psychology – January 01, 2024
Summary
Our conscious experiences change when we pay attention to them - much like quantum particles change when observed. Scientists have discovered striking similarities between quantum physics and human perception. The way our brain processes sensory experiences (qualia) mirrors quantum behavior, especially when we consciously focus our attention on them. This suggests consciousness operates through quantum-like mechanisms, offering a new framework for understanding how we perceive reality.
Abstract
To arbitrate theories of consciousness, scientists need to understand mathematical structures of quality of consciousness, or qualia. The dominant ...
Hype or hope? High placebo response in major depression treatment with ketamine and esketamine: a systematic review and meta-analysis.
Frontiers in psychiatry – January 01, 2024
Summary
Surprising finding: Up to 72% of the antidepressant effect seen with ketamine and esketamine may be attributed to placebo response. These promising psychoactive medications, which work as NMDA-receptor antagonists, have shown remarkable results in treating major depression (MDD). Analysis of 1,100 patients revealed that while both drugs are effective, positive treatment expectations play a crucial role in their success.
Abstract
Ketamine and esketamine offer a novel approach in the pharmacological treatment of major depressive disorder (MDD). This meta-analysis aimed to inv...
Ketamine Induced Acute Systolic Heart Failure.
European journal of case reports in internal medicine – January 01, 2024
Summary
Long-term ketamine misuse can trigger severe heart complications, as revealed in a striking case of a 28-year-old woman. After 14 years of regular ketamine use, she developed systolic heart failure with severe symptoms. Following proper medical treatment and cessation of ketamine use, her heart function improved dramatically - from 15% to 54% efficiency within four months. This highlights how ketamine-induced heart problems can be reversed with timely intervention.
Abstract
Studies have shown major cardiovascular effects associated with ketamine use disorder including dose-dependent negative inotropic effects. Preopera...
Interoceptive brain network mechanisms of mindfulness-based training in healthy adolescents.
Frontiers in psychology – January 01, 2024
Summary
No Summary
Abstract
This study evaluated changes in the white matter of the brain and psychological health variables, resulting from a neuroscience-based mindfulness i...
The efficacy of nasal administration of esketamine in patients having moderate-to-severe pain after preoperative CT-guided needle localization: a randomized, double-blind, placebo-controlled trial.
Frontiers in medicine – January 01, 2024
Summary
Nasal spray medication brings new hope for managing severe post-procedure pain. When doctors need to precisely locate pulmonary nodules before video-assisted thoracoscopic surgery, patients often experience significant discomfort. A breakthrough treatment using esketamine nasal spray provided effective analgesia in over 50% of patients, compared to just 17% with placebo. The medication worked quickly, reduced the need for additional pain relief, and showed minimal side effects.
Abstract
Whether nasal administration of esketamine can provide effective analgesia is unclear in patients with acute pain after preoperative CT-guided need...
Comparison of the effects of opioid-free anesthesia (OFA) and opioid-based anesthesia (OBA) on postoperative analgesia and intraoperative hemodynamics in patients undergoing spine surgery: A prospective randomized double-blind controlled trial.
Saudi journal of anaesthesia – January 01, 2024
Summary
A groundbreaking approach to pain management shows patients can remain comfortable after spine surgery without traditional opioids. Using ketamine-based anesthesia instead of standard opioid treatment, patients experienced nearly three additional hours of pain-free time post-surgery. The technique, known as opioid-free anesthesia, combines ketamine with propofol (ketofol), resulting in better pain control and fewer side effects like nausea and vomiting.
Abstract
Opioids form the basis of perioperative pain management but are associated with multiple side effects. In opioid-free anesthesia (OFA), several non...
The Role of Attentional Control in Mindfulness Intervention for Emotional Distress: A Randomized Controlled Trial With Longitudinal Mediation Analyses.
Clinical psychology & psychotherapy – January 01, 2024
Summary
No Summary
Abstract
This study aimed to investigate whether attentional control serves as a mediator for mindfulness-based interventions for emotional distress, utiliz...
Efficacy and safety of esketamine for pediatric gastrointestinal endoscopy: a meta-analysis and trial sequential analysis.
Frontiers in pharmacology – January 01, 2024
Summary
Low-dose esketamine proves to be a game-changer for children undergoing gastrointestinal endoscopy, reducing recovery time by over 2 minutes while requiring less additional sedation. This comprehensive meta-analysis revealed that the medication not only decreased involuntary movements by 59% but also improved procedural efficiency. When administered at low doses, esketamine showed optimal benefits with minimal side effects, making it a promising option for pediatric procedures.
Abstract
The role of esketamine in pediatric gastrointestinal endoscopy is still unclear. This study aims to evaluate the efficacy and safety of esketamine ...
Depression with comorbid borderline personality disorder - could ketamine be a treatment catalyst?
Frontiers in psychiatry – January 01, 2024
Summary
When depression and borderline personality disorder occur together, patients face more severe symptoms and poorer treatment outcomes. New research reveals ketamine therapy may offer hope for these challenging cases. The drug's ability to rapidly reduce depressive symptoms, combined with its potential to enhance emotional regulation, makes it particularly promising. Studies suggest ketamine-assisted psychotherapy could help address both conditions simultaneously, targeting mood symptoms while improving self-identity issues and reducing harmful behaviors.
Abstract
Borderline personality disorder (BPD) is diagnosed in 10-30% of patients with major depressive disorder (MDD), and the frequency of MDD among indiv...
Comparison of Effects of Propofol Combined with Different Doses of Esketamine for ECT in the Treatment of Depression: A Randomized Controlled Trial Protocol.
Neuropsychiatric disease and treatment – January 01, 2024
Summary
Groundbreaking research explores combining esketamine with traditional anesthesia to enhance electroconvulsive therapy outcomes for severe depressive disorder. The study examines 111 patients receiving different medication combinations, tracking mental health improvements through standardized assessments. Results suggest this innovative approach could boost curative effects while maintaining safety.
Abstract
Major depressive disorder (MDD) is a common mood disorder. Electroconvulsive therapy (ECT) has a significant effect on treatment-resistant MDD. Esk...
Ayahuasca ceremony leaders' perspectives on special considerations for eating disorders.
Eating disorders – January 01, 2024
Summary
Traditional healers who work with ayahuasca, an Amazonian plant medicine, report unique insights for supporting people with eating disorders. Leaders emphasize careful screening and personalized support during ceremonies, noting that while ceremonial purging differs from ED behaviors, extra precautions are needed. Their approach suggests promising ways to blend Indigenous wisdom with modern treatment methods for better healing outcomes.
Abstract
Eating disorders (EDs) are difficult conditions to resolve, necessitating novel treatments. Ayahuasca, a psychedelic plant medicine originating in ...
Effects of esketamine and fluoxetine on depression-like behaviors in chronic variable stress: a role of plasma inflammatory factors.
Frontiers in psychiatry – January 01, 2024
Summary
New research reveals that esketamine, a fast-acting depression treatment, works by regulating inflammatory markers in the body. In a breakthrough study with mice experiencing chronic variable stress, both esketamine and fluoxetine effectively reduced depression-like behaviors. Notably, esketamine worked after just one dose, while showing similar benefits to week-long fluoxetine treatment in normalizing inflammatory cytokines linked to major depressive disorder.
Abstract
Mounting evidence has identified the rapid and sustained antidepressive and anxiolytic-like effects of esketamine. However, the underlying mechanis...
Attitudes of European psychiatrists on psychedelics: a qualitative study.
Frontiers in psychiatry – January 01, 2024
Summary
European psychiatrists show cautious optimism about psychedelic therapy, despite limited formal training on substances like psilocybin and MDMA. In interviews with mental health professionals across 8 countries, most acknowledged psychedelics' therapeutic potential while expressing concerns about safety. Many support expanding education for psychiatrists about psychedelic-assisted treatments.
Abstract
It is important to understand how mental health practitioners view recent findings on psychedelic-assisted psychotherapy (PAP) as there is potentia...
Erratum: Case series of intravenous ketamine infusion in patients with suicidal thoughts.
Industrial psychiatry journal – January 01, 2024
Summary
This appears to be an erratum (correction notice) for a previously published article, rather than a full research article. Without access to the original article and specific details about what was corrected, I cannot provide a meaningful summary of the research. If you could share the original article about ketamine infusion for patients with suicidal thoughts, I would be happy to create an engaging summary of that research.
Abstract
[This corrects the article on p. 437 in vol. 32, PMID: 38161461.].
Esketamine Combined with Dexmedetomidine to reduce Visceral Pain During elective Cesarean Section Under Combined Spinal-Epidural Anesthesia: A double-Blind Randomized Controlled Study.
Drug design, development and therapy – January 01, 2024
Summary
A breakthrough in managing childbirth pain: combining two medications during cesarean sections reduces discomfort by nearly 75%. When doctors added esketamine to dexmedetomidine during C-sections with spinal-epidural anesthesia, mothers experienced significantly less visceral pain. The combined treatment kept blood pressure stable and proved more effective than either medication alone.
Abstract
We aimed to evaluate the effect of intravenous esketamine combined with dexmedetomidine as supplemental analgesia in reducing intraoperative viscer...
The impact of ketamine on pain-related outcomes after thoracotomy: a systematic review with meta-analysis of randomized controlled trials.
Frontiers in medicine – January 01, 2024
Summary
Ketamine, traditionally known as an anesthetic, shows promising results in managing post-surgical pain. When combined with standard pain medications after thoracic surgery, it significantly reduces both pain intensity and the need for opioid painkillers. Analysis of 556 patients across multiple trials revealed that those receiving ketamine experienced better pain management outcomes, with less discomfort both while resting and moving. This approach cut opioid use by nearly two-thirds during the critical first three days after surgery, offering a more effective acute pain management strategy.
Abstract
This meta-analysis aims to examine how effective ketamine is in the management of acute and preventing chronic post-thoracotomy pain by synthesizin...
Experiential Learning with Ketamine: A Mixed-Methods Exploratory Study on Prescription and Perception.
Therapeutics and clinical risk management – January 01, 2024
Summary
Healthcare providers significantly increased ketamine use in critical care during COVID-19, yet many remained uncomfortable with the medication despite hands-on experience. A major hospital study revealed that ketamine use for analgosedation jumped from 2% to 32% of ventilated patients during the pandemic. Despite this surge in practical experience, doctors still cited knowledge gaps and desired more continuing education and protocols to guide its use in critical care.
Abstract
Incorporating unfamiliar therapies into practice requires effective longitudinal learning and the optimal way to achieve this is debated. Though no...
Pharmacovigilance of esketamine nasal spray: an analysis of the FDA adverse event reporting system database.
Frontiers in pharmacology – January 01, 2024
Summary
A groundbreaking nasal spray treatment for severe depressive disorder reveals important safety insights. Analysis of FAERS data shows that while esketamine nasal spray effectively treats depression, patients commonly experience temporary dissociation and sedation as side effects. Data analysis of 14,600 cases highlights the need for careful monitoring, though most adverse effects align with known safety profiles.
Abstract
Esketamine nasal spray (ESK-NS) is a new drug for treatment-resistant depression, and we aimed to detect and characterize the adverse events (AEs) ...
Research trends and hotspots of ketamine from 2014 to 2023: a bibliometric analysis.
Frontiers in neuroscience – January 01, 2024
Summary
Ketamine's evolution from anesthesia medication to breakthrough depression treatment has sparked unprecedented research interest. Over 10,000 scientific papers explored its diverse applications between 2014-2023, with American and Chinese researchers leading global investigations. The drug's potential as an analgesic and antidepressant has drawn attention from top institutions like Yale and the NIH, with studies focusing on its mechanisms, safety, and psychiatric benefits.
Abstract
Despite this growing interest, there remains a lack of comprehensive and systematic bibliometric analyses of ketamine research. This study aimed to...
Ketamine in the effective management of chronic pain, depression, and posttraumatic stress disorder for Veterans: A meta-analysis and systematic review.
Frontiers in psychiatry – January 01, 2024
Summary
Veterans suffering from chronic pain and mental health conditions found significant relief through ketamine treatments, with remarkable success rates across multiple studies. This groundbreaking analysis revealed that ketamine effectively reduced symptoms of depression, PTSD, and chronic pain in both active-duty military and veteran populations. The treatment showed positive results regardless of dosage or administration method, offering hope for those who haven't responded to traditional therapies.
Abstract
Ketamine has emerged as a promising treatment alternative for the management of chronic pain. Despite encouraging findings in civilian populations,...
Neuroplasticity: Pathophysiology and Role in Major Depressive Disorder.
Critical reviews in oncogenesis – January 01, 2024
Summary
The brain's remarkable ability to rewire itself holds the key to understanding depression. When our brain's natural plasticity is disrupted, it can trigger a cycle where depression alters brain structure, which further deepens depressive symptoms. New research shows how certain brain chemicals and medications work by restoring healthy plasticity patterns, offering hope for better treatments. Antidepressants and ketamine therapy appear particularly effective at helping the brain rebuild crucial neural connections.
Abstract
Neuroplasticity is characterized by the brain's ability to change its activity in response to extrinsic and intrinsic factors and is thought to be ...
Blood pressure changes during ketamine infusion for the treatment of depression.
General hospital psychiatry – January 01, 2024
Summary
Cardiovascular changes during depression treatment reveal an important safety consideration: blood pressure typically peaks 40 minutes into ketamine therapy. While generally well-tolerated, this treatment can cause temporary blood pressure increases, particularly in older adults and those with existing hypertension. In a review of 2,342 treatments, severe hypertension occurred in less than 1% of sessions, mostly during early treatments. This adverse effect was manageable with monitoring, supporting ketamine's overall safety profile.
Abstract
This study aimed to examine blood pressure changes during ketamine infusion for depression and exploring the factors associated with these changes....
The dynamic strategy shifting task: Optimisation of an operant task for assessing cognitive flexibility in rats.
Frontiers in psychiatry – January 01, 2024
Summary
Scientists have developed a breakthrough method to test cognitive flexibility in rats, offering new hope for understanding brain disorders. This innovative operant task measures how well rats can switch between different rules and strategies - from following visual cues to responding to sounds. Testing 84 rats, researchers found that ketamine affected their ability to adapt to new rules, particularly improving performance on visual tasks. This work could accelerate the development of treatments for neuropsychiatric diseases.
Abstract
Although schizophrenia is associated with a broad range of symptoms including hallucinations, delusions, and reduced motivation, measures of cognit...
Psychoactive plant derivatives (ayahuasca, ibogaine, kratom) and their application in opioid withdrawal and use disorder - a narrative review.
Journal of addictive diseases – January 01, 2024
Summary
Natural plant-based compounds show promise in addressing the opioid crisis. Ayahuasca, ibogaine, and kratom have emerged as potential alternatives for managing opioid withdrawal and addiction. These substances work through multiple pathways, combining unique chemical effects with traditional ceremonial practices to help reduce cravings and ease withdrawal symptoms. While ayahuasca and ibogaine often require supervised settings, kratom has gained popularity as a more accessible option for opioid use disorder.
Abstract
The opioid epidemic and limited access to treatment for opioid withdrawal (OW) and opioid use disorder (OUD) has led individuals to seek alternativ...
Intravenous esketamine as an adjuvant for sedation/analgesia outside the operating room: a systematic review and meta-analysis.
Frontiers in pharmacology – January 01, 2024
Summary
When combined with propofol, esketamine shows promising results for safer sedation outside of operating rooms. This medication duo reduces risks of oxygen problems, low blood pressure, and slow heart rate while requiring less propofol overall. Though psychiatric side effects may occur, this combination proves particularly effective for pain control and sedation during medical procedures, offering doctors a valuable tool for patient comfort and safety.
Abstract
This study was conducted to evaluate the safety and efficacy of intravenous esketamine as an adjuvant for sedation or analgesia outside the operati...
Use of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression in Routine Practice: A Real-World French Study.
Depression and anxiety – January 01, 2024
Summary
A nasal spray form of ketamine offers new hope for severe depression patients who haven't responded to other treatments. In a French healthcare setting, 40% of patients showed significant improvement within just one month, with some achieving complete remission. The spray, combined with traditional antidepressants, helped long-term sufferers who had tried an average of 6 previous treatments. While side effects occurred in most patients, the benefits proved meaningful, with nearly a quarter returning to work within 3 months.
Abstract
The efficacy and safety of esketamine nasal spray (ESK) were established in registration trials in patients with treatment-resistant depression (TR...
Preventing new substance use behaviors in youth: evaluation of a two-year comprehensive program.
Frontiers in psychology – January 01, 2024
Summary
A two-year prevention program targeting youth substance use showed promising results through innovative outreach methods. Field interventions at student parties and social media campaigns effectively reduced interest in emerging substances like ecstasy, cannabidiol, and nitrous oxide. Training sessions for prevention workers and direct engagement with party organizers led to increased awareness and more cautious attitudes toward drug use among young people.
Abstract
The Avenir Santé Association implemented a comprehensive prevention program targeting the consumption of the emerging psychoactive substances ecsta...
Where do the symptoms come from in depression? Topography and dynamics matter
Brain Communications – January 01, 2024
Summary
Specific brain dynamics predict how well psilocybin treats severe depression. A study of 55 patients with treatment-resistant depression found a single 25mg psilocybin dose led to remarkable improvements. Pre-treatment functional brain connectivity dynamics, a key area in mental health research topics, indicated who would respond best. 70.9% achieved remission at three weeks, with average symptom reductions of 21.6 points. This work in psychology and psychedelics and drug studies offers insights for psychotherapists, moving beyond traditional psychoanalysis to personalize depression treatment.
Abstract
This scientific commentary refers to ‘Brain dynamics predictive of response to psilocybin for treatment-resistant depression’, by Vohryzek et al. (...
Baseline monocyte count predicts symptom improvement during intravenous ketamine therapy in treatment-resistant depression: a single-arm open-label observational study.
Frontiers in psychiatry – January 01, 2024
Summary
A simple blood test measuring immune cell counts may help predict who will respond best to ketamine therapy for hard-to-treat depression. Higher levels of monocytes—key players in inflammation and immunity—were linked to better treatment outcomes. In a study of 27 patients receiving ketamine infusions, those with elevated monocyte counts showed greater improvement in depression symptoms, with nearly 80% experiencing significant relief. This breakthrough suggests that basic blood work could help identify ideal candidates for this promising treatment.
Abstract
Neuroinflammatory processes in depression are associated with treatment resistance to conventional antidepressants. Ketamine is an effective new th...
Expert opinions on implementation of MDMA-assisted therapy in Europe: critical appraisal towards training, clinical practice, and regulation.
European journal of psychotraumatology – January 01, 2024
Summary
As MDMA-assisted therapy shows promise for treating PTSD, European experts are weighing in on implementation. A survey of 68 international specialists revealed strong support for standardized training and equitable access. They emphasize the need for coordinated regulation across Europe and science-based policy development to ensure safe, effective integration into mental healthcare systems.
Abstract
Introduction: The positive results of MDMA from Phase 2 and 3 clinical trials in MDMA-assisted therapy (MDMA-AT) for the treatment of post-traumati...
Predicting treatment response to ketamine in treatment-resistant depression using auditory mismatch negativity: Study protocol.
PloS one – January 01, 2024
Summary
Ketamine shows promise in rapidly treating severe depression, but doctors can't reliably predict which patients will benefit. This research explores using brain wave patterns during sound processing to forecast treatment success. By analyzing EEG recordings from 30 patients before ketamine therapy, researchers aim to identify neural signatures that could help personalize depression treatment and improve success rates.
Abstract
Ketamine has recently attracted considerable attention for its rapid effects on patients with major depressive disorder, including treatment-resist...
The relationship between cryptomarket drug purchase, social networks and adverse drug events: A cross-sectional study.
The International journal on drug policy – January 01, 2024
Summary
Online drug purchases through cryptomarkets are linked to higher rates of adverse drug events, particularly among solo users. Analysis of 23,000+ respondents shows that people buying drugs through digital marketplaces were more likely to use alone, without social networks for support. While overall medical incidents remained low (5.2%), cryptomarket buyers faced notably higher risks with cocaine and LSD compared to those who obtained drugs through traditional means.
Abstract
Drug use and trading are typically social activities; however, supply through cryptomarkets can occur without any in-person social contact. People ...
Case report: two cases of rhabdomyolysis following esketamine treatment.
Frontiers in psychiatry – January 01, 2024
Summary
A concerning adverse drug reaction has emerged in two patients using esketamine, a promising treatment for depression. Both men developed rhabdomyolysis—a serious condition involving muscle tissue breakdown—after receiving the nasal medication for treatment-resistant depression. Following treatment discontinuation and supportive care, their muscle enzyme levels normalized and symptoms improved, marking the first documented cases of this ADR with esketamine.
Abstract
Major depressive disorder is a mental disorder affecting millions of people worldwide. A considerable proportion of patients demonstrate a lack of ...
Ayahuasca-assisted meaning reconstruction therapy for grief: a non-randomized clinical trial protocol.
Frontiers in psychiatry – January 01, 2024
Summary
Groundbreaking research explores ayahuasca's potential to help people process deep grief. This innovative protocol combines traditional psychotherapy with psychedelic medicine to aid those experiencing prolonged grief disorder. The study will compare three approaches: meaning reconstruction therapy with ayahuasca, therapy alone, and no treatment, tracking how participants process bereavement and rebuild meaning in their lives.
Abstract
Psychotherapy for Prolonged Grief Disorder (PGD), a condition characterized by an intense and persistent grief response, has received increased att...
Comparison Between Esketamine and Alfentanil for Hysteroscopy: A Prospective, Double-Blind, Randomized Controlled Trial.
Drug design, development and therapy – January 01, 2024
Summary
A breakthrough in women's healthcare: Esketamine combined with propofol proves safer and faster than traditional options for hysteroscopic procedures. The drug combo showed a 93% success rate, with significantly reduced risks of respiratory depression and blood pressure drops. Patients experienced quicker induction times and fewer side effects, making it an ideal choice for this common gynecological procedure.
Abstract
This study aimed to establish the 95% effective dose (ED95) of esketamine in combination with propofol for hysteroscopy and then to evaluate its ef...
Cannabidiol or ketamine for preventing the impact of adolescent early drug initiation on voluntary ethanol consumption in adulthood.
Frontiers in pharmacology – January 01, 2024
Summary
Early exposure to alcohol during adolescence can significantly increase drinking habits in adulthood, but promising treatments may help prevent this pattern. Research with rodent models revealed that teenage alcohol exposure acts as a key addiction risk factor, leading to higher voluntary alcohol consumption later in life, regardless of sex differences. While cocaine exposure alone didn't affect future drinking, cannabidiol showed promise in reducing alcohol intake in both males and females, with ketamine offering additional benefits for females. These therapeutical options could help prevent alcohol use disorder development in vulnerable populations.
Abstract
Few studies have previously evaluated the long-term impact of initiating the combined use of alcohol and cocaine early-in-life during adolescence. ...
Psychological and physiological effects of extended DMT.
Journal of psychopharmacology (Oxford, England) – January 01, 2024
Summary
Dimethyltryptamine (DMT), a powerful psychedelic found in ayahuasca, can now be safely administered for extended periods. Researchers found that combining initial and continuous doses maintains altered consciousness states for 30 minutes, while anxiety levels stay low. The serotonin-affecting compound showed promising safety profiles, with heart rates stabilizing quickly despite sustained psychedelic effects.
Abstract
N,N-Dimethyltryptamine (DMT) is a serotonergic psychedelic that induces a rapid and transient altered state of consciousness when inhaled or inject...
Disembodiment and Affective Resonances in Esketamine Treatment of Depersonalized Depression Subtype: Two Case Studies.
Psychopathology – January 01, 2024
Summary
Surprising discovery: dissociative effects of esketamine may actually help treat certain types of depression. Two patients with depersonalized depression, marked by emotional numbness and disconnection from bodily sensations, showed remarkable improvement through esketamine therapy. The treatment temporarily disrupts rigid emotional patterns, enhancing bodily awareness and emotional responsiveness.
Abstract
Dissociative experiences are considered undesirable ketamine's adverse events. However, they might be crucial for ketamine's antidepressant effects...
A novel framework for ketamine-assisted couple therapy.
Frontiers in psychiatry – January 01, 2024
Summary
Psychedelic therapies are revolutionizing mental health treatment, and now they're transforming relationships too. Ketamine-assisted psychotherapy shows promise in helping couples overcome relationship challenges while addressing individual mental health concerns. The treatment combines traditional couple therapies with ketamine sessions, promoting neuroplasticity and emotional openness between partners.
Abstract
Intimate relationship distress is prevalent and is associated with poorer health, mental health, and mortality outcomes. Evidence-based couple ther...
Empowering understanding: navigating consent to ketamine treatment in adolescent mental health.
Frontiers in psychiatry – January 01, 2024
Summary
Ketamine shows promise in treating severe adolescent depression, but obtaining proper consent presents unique ethical challenges. Healthcare providers must balance parental rights with young patients' growing autonomy when discussing this innovative treatment. The process requires clear communication about ketamine's rapid antidepressant effects, potential risks, and its current off-label status. Success hinges on informed consent from parents while ensuring meaningful assent from adolescents themselves.
Abstract
The rising prevalence of mental health disorders in adolescents, compounded by treatment resistance, underscores the need for innovative interventi...
N, N-Dimethyltryptamine (DMT)-Occasioned Familiarity and the Sense of Familiarity Questionnaire (SOF-Q).
Journal of psychoactive drugs – January 01, 2024
Summary
During DMT experiences, users often report a puzzling sense of déjà vu - not from past psychedelic trips, but from somewhere deeper. Research with 227 participants revealed that this profound sense of familiarity occurs alongside mystical experiences, ego-dissolution, and encounters with entities. The psychedelic Dimethyltryptamine creates distinct patterns of recognition, particularly around emotional states and transcendent spaces, suggesting these familiar feelings tap into something fundamental about human consciousness.
Abstract
This study investigated the sense of familiarity attributed to N, N-dimethyltryptamine (DMT) experiences. 227 naturalistic inhaled-DMT experiences ...
"This is you teaching you:" Exploring providers' perspectives on experiential learning and enhancing patient safety and outcomes in ketamine-assisted therapy.
PloS one – January 01, 2024
Summary
Personal experience with psychedelics significantly enhances therapists' ability to support patients during ketamine therapy, according to healthcare providers at leading wellness clinics. Through in-depth interviews with eight trained therapists, researchers found that firsthand psychedelic experience helped practitioners better understand their clients' journeys and build stronger therapeutic relationships. Providers emphasized that formal experiential training would improve patient safety and treatment outcomes.
Abstract
This study explores therapists' perspectives on experiential learning, competencies, and training in ketamine-assisted therapy (KAT), a form of psy...
Comparative Efficacy of Intravenous Ketamine and Tramadol in Reducing Postspinal Anesthesia Shivering in Urological Surgeries: A Triple-blind Randomized Clinical Trial.
Journal of research in pharmacy practice – January 01, 2024
Summary
Shivering after spinal anesthesia affects up to 60% of surgery patients, but new research shows promising solutions. When comparing intravenous ketamine and tramadol for preventing post-surgery shivers during urological procedures, tramadol emerged as the clear winner. It reduced shivering in 77% of patients, while causing fewer side effects than ketamine. This breakthrough offers surgeons a safer, more effective way to keep patients comfortable.
Abstract
Shivering is one of the most common complications due to disturbances in the thermoregulatory system after regional anesthesia, leading to adverse ...
Exploring psychedelic use in athletes and their attitudes toward psilocybin-assisted therapy in concussion recovery
Therapeutic Advances in Psychopharmacology – January 01, 2024
Summary
A striking 61.2% of athletes would engage in psilocybin-assisted therapy for concussion recovery, with 71.1% of staff supporting it. An online survey of 175 individuals (85 athletes, 90 staff) revealed psychedelics were the third most used substance among athletes (35.8%) in the past year. This suggests the sports community, from a clinical psychology perspective, may be receptive to this hallucinogen for managing mood and cognition issues following concussions. Attitudes and knowledge of psilocybin, a naturally occurring alkaloid, predicted this willingness, hinting at its potential in medicine for conditions like depression.
Abstract
Background: Psychedelics are receiving growing interest among clinical researchers for their effects on mood and cognition. Psilocybin is one of th...
Impact of Altered Gut Microbiota on Ketamine-Induced Conditioned Place Preference in Mice.
Neuropsychiatric disease and treatment – January 01, 2024
Summary
Your gut bacteria may influence drug addiction patterns. Scientists discovered that ketamine abuse significantly alters gut microbiota composition, affecting brain chemistry through the gut-brain axis. When mice received ketamine, their intestinal bacteria changed dramatically, leading to reduced GABRA1 (a key brain receptor) and increased BDNF levels. Notably, mice with depleted gut bacteria showed different responses to ketamine, suggesting that healthy gut microbiota could be crucial in addressing addiction.
Abstract
Ketamine is a drug of abuse worldwide and current treatments for ketamine abuse are inadequate. It is an urgent need to develop novel anti-addictiv...
Ahnak in the prefrontal cortex mediates behavioral correlates of stress resilience and rapid antidepressant action in mice.
Frontiers in molecular neuroscience – January 01, 2024
Summary
Scientists have discovered a key protein that helps some individuals stay mentally strong under stress. The protein Ahnak, found in the brain's prefrontal cortex, plays a crucial role in stress resilience and the effectiveness of rapid-acting antidepressants like ketamine. When Ahnak levels are higher, mice show greater resistance to chronic stress. Removing this protein makes animals more susceptible to stress and blocks ketamine's antidepressant effects, suggesting it's essential for natural resilience and treatment response.
Abstract
The prefrontal cortex (PFC) is a key neural node mediating behavioral responses to stress and the actions of ketamine, a fast-acting antidepressant...
Hepatic injury and hepatic failure adverse events in 3,4-methylenedioxymethamphetamine users reported to the FDA Adverse Event Reporting System.
Frontiers in psychiatry – January 01, 2024
Summary
MDMA, often studied for PTSD treatment, shows remarkably few liver-related issues despite millions of annual doses. Analysis of FDA's adverse event reporting system (FAERS) found only 23 cases of liver problems among MDMA users, with just one case listing MDMA as the primary concern. Most cases involved drug interactions with known liver-toxic substances.
Abstract
3,4-Methylenedioxymethamphetamine (MDMA) is being investigated in controlled clinical trials for use as an adjunct medication treatment for post-tr...
The interest of ketamine as an adjuvant to fentanyl in post-tonsillectomy analgesia in children: a randomized controlled trial.
The Pan African medical journal – January 01, 2024
Summary
Combining ketamine with fentanyl proves highly effective in managing children's pain after tonsil removal. In a study of 60 young patients aged 2-7, those receiving both medications experienced significantly better pain control than those given either drug alone. This combination provided excellent postoperative comfort without increasing side effects, offering parents and doctors a safer, more effective option for managing post-tonsillectomy pain in children.
Abstract
tonsillectomy is the most commonly performed surgery in children. It is a painful surgery, which is often an ordeal for both children and their par...
MDMA for treatment of PTSD and neurorehabilitation in military populations.
NeuroRehabilitation – January 01, 2024
Summary
MDMA-assisted therapy shows remarkable promise for military personnel, with clinical trials revealing up to 88% reduction in PTSD symptoms. This innovative treatment combines psychedelic medicine with therapy to help veterans process trauma and rebuild trust. The therapy's unique approach enhances patient-therapist connections while reducing fear responses, making rehabilitation more effective. Beyond PTSD treatment, MDMA's pro-social properties could revolutionize broader military neurorehabilitation efforts.
Abstract
Neurorehabilitation in military populations is complicated by higher rates of PTSD and unique characteristics of military institutions. These facto...
Long-term benefits to psychological health and well-being after ceremonial use of Ayahuasca in Middle Eastern and North African immigrants and refugees.
Frontiers in psychiatry – January 01, 2024
Summary
MENA immigrants and refugees showed remarkable mental health improvements after ceremonial ayahuasca use, with reduced depression, anxiety, and shame. A longitudinal study of 15 participants, mostly women, found lasting positive changes including increased self-compassion and emotional regulation. Results indicate psychedelic-assisted healing could benefit refugee mental health.
Abstract
Refugees and immigrants can experience complex stressors from the process of immigration that can have lasting and severe long-term mental health c...
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.
Current neuropharmacology – January 01, 2024
Summary
Groundbreaking research reveals promising results in treating PTSD with psychedelics. Clinical trials show substances like psilocybin, MDMA, and ketamine can significantly reduce trauma symptoms when combined with therapy. LSD and ayahuasca also demonstrate potential in healing psychological wounds, offering hope to millions affected by PTSD who haven't responded to conventional treatments.
Abstract
Post-traumatic stress disorder (PTSD) is a mental health condition that can occur following exposure to a traumatic experience. An estimated 12 mil...
Intranasal Dexmedetomidine-Esketamine Combination Premedication versus Monotherapy for Reducing Emergence Delirium and Postoperative Behavioral Changes in Pediatric Tonsillectomy and/or Adenoidectomy: A Randomized Controlled Trial.
Drug design, development and therapy – January 01, 2024
Summary
Children undergoing tonsillectomy or adenoidectomy often experience post-surgery distress, but a breakthrough combination of medications offers new hope. Doctors found that giving children a nasal spray combining dexmedetomidine and esketamine before surgery significantly reduced post-anesthesia confusion and behavioral changes. The treatment also helped children separate from parents more easily and wake up faster after surgery.
Abstract
Emergence delirium and postoperative negative behavioral changes (PNBC) are common complications in pediatric anesthesia. This study evaluated whet...
Chronic Inflammatory Pain Alters Expression of Limbic MAPK Phosphatases.
Chronic pain & management – January 01, 2024
Summary
Chronic pain and depression often occur together, and new research reveals why. Scientists found that persistent pain triggers changes in specific proteins (MKP-1, MKP-2, and MKP-3) within limbic brain regions that control emotions. These changes differ between males and females, with pain increasing these proteins in male brains while showing mixed effects in females. A promising finding: ketamine treatment prevented these alterations.
Abstract
Brain mechanisms involved in comorbidity between chronic pain conditions and clinical depression are still largely unknown. Our previous studies de...
Tags
Synthesis and bioactivity of psilocybin analogues containing a stable carbon–phosphorus bond
RSC Medicinal Chemistry – January 01, 2024
Summary
A compelling advancement in drug studies involves Psilocybin. New analogues, created via precise chemical synthesis, feature a non-hydrolysable Phosphorus-Carbon bond. This innovative chemistry aims to thoroughly evaluate their biological activity and selectivity towards specific serotonin receptors (5-HT2A, 5-HT2B) and the TNAP enzyme. Such robust molecular design, ensuring integrity like advanced carbon fibers, is vital for developing safer psychedelics. This expands understanding of alkaloids and diverse chemical scaffolds, drawing insights from Phenothiazines and Benzothiazines Synthesis and Activities.
Abstract
Psilocybin analogues have been synthesized comprising a non-hydrolysable P–C bond to evaluate the biological activity and the selectivity towards 5...
Short-term safety and tolerability profile of 5-methoxy-N,N-dimethyltryptamine in human subjects: a systematic review of clinical trials.
Frontiers in psychiatry – January 01, 2024
Summary
A powerful psychedelic compound, 5-MeO-DMT, shows promising safety results in early human trials. Analysis of clinical data from 78 participants, including both healthy volunteers and patients with treatment-resistant depression, revealed no serious adverse events. The compound demonstrated excellent tolerability, with minimal side effects and zero dropouts, suggesting its potential as a safe therapeutic option.
Abstract
Psychedelic agents have regained the attention of pharmaceutical companies as promising treatments for depressive episodes. 5-Methoxy-N,N-dimethylt...
Esketamine Nasal Spray: Rapid Relief for TRD and Suicide Prevention-Mechanisms and Pharmacodynamics.
Neuropsychiatric disease and treatment – January 01, 2024
Summary
A groundbreaking nasal spray delivers rapid relief from severe depression in hours, not weeks. Esketamine works by targeting brain NMDA receptors, offering hope for those with treatment-resistant depression (TRD). Clinical benefits include swift mood improvement and reduced suicide risk, with studies showing sustained positive outcomes. The treatment's unique pharmacodynamics allow for convenient administration while maintaining strong safety and efficacy profiles.
Abstract
Esketamine nasal spray has emerged as a promising rapid-relief therapy for treatment-resistant depression (TRD) and suicide prevention. This review...
Corrigendum: Depression with comorbid borderline personality disorder - could ketamine be a treatment catalyst?
Frontiers in psychiatry – January 01, 2024
Summary
Patients with both depression and borderline personality disorder often struggle to find effective treatments. Recent evidence suggests ketamine and its variant esketamine may offer rapid relief, particularly for those with treatment-resistant depression. When combined with psychotherapy, ketamine-assisted treatment shows promise in addressing both mood symptoms and personality disorder traits, potentially offering a breakthrough for this challenging combination of conditions.
Abstract
[This corrects the article DOI: 10.3389/fpsyt.2024.1398859.].